We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

TATAA Strengthens Quality Assurance Program

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

TATAA Biocenter is strengthening its quality assurance program by introducing RNA quality assessment using Advanced Analytical Technologies, Inc. (“AATI”) Fragment Analyzer™ into its company’s Standard Operating Procedures (SOPs) for expression profiling. “As we are analysing more and more complex samples, including preserved materials such as formalin fixed and paraffin embedded tissues, soils and sewer samples, and other aggressive matrices, the quality of the extracted nucleic acids becomes critical for meaningful analysis. Much money can be saved by identifying problems at an early stage and either discarding poor quality samples or replacing them. With the Fragment Analyzer™ we can do this in high throughput, at acceptable cost and with greatest confidence”, says Dr. Mikael Kubista, founder and CEO of TATAA Biocenter.

Since the Fragment Analyzer™ product launch in early 2012, AATI has placed over 275 units worldwide and has quickly become the technology solution standard to which all others are measured within the rapidly expanding nucleic acids analysis industry.

“We couldn’t be more pleased to have an organization with the creditability of TATAA Biocenter added to our customer list. The Fragment Analyzer™ was designed and built with end-users first in mind,” said Dr. Steven Lasky, founder and CEO of AATI. “When we speak with potential users of the Fragment Analyzer™ we hear the same problem, they are frustrated with the existing competitive solutions; lack of ability to scale with their throughput, lack of reproducible resolution and lack of ability to perform multiple assessments on a single machine. Our proprietary technology allows us to streamline sample processing steps, analyze PCR and NGS library DNA fragments, total and messenger RNA, genomic DNA and DNA mutation detection assays all under one foot print. Together these attributes facilitate an enhanced return on capital for our customers.”